Cargando…
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer
BACKGROUND: Pro-survival Bcl-2 family members can promote cancer development and contribute to treatment resistance. Head and neck squamous cell carcinoma (HNSCC) is frequently characterized by overexpression of anti-apoptotic Bcl-2 family members. Increased levels of these anti-apoptotic proteins h...
Autores principales: | Zerp, Shuraila F., Stoter, T. Rianne, Hoebers, Frank J. P., van den Brekel, Michiel W. M., Dubbelman, Ria, Kuipers, Gitta K., Lafleur, M. Vincent M., Slotman, Ben J., Verheij, Marcel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520130/ https://www.ncbi.nlm.nih.gov/pubmed/26223311 http://dx.doi.org/10.1186/s13014-015-0474-9 |
Ejemplares similares
-
AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis
por: Zerp, Shuraila F, et al.
Publicado: (2009) -
Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
por: Zerp, Shuraila F., et al.
Publicado: (2020) -
(99m)Tc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy
por: Hoebers, Frank J. P., et al.
Publicado: (2007) -
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer
por: Heukelom, Jolien, et al.
Publicado: (2013) -
Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients
por: van der Heijden, Martijn, et al.
Publicado: (2019)